Kolanu Nikhil Deep, Syeda Zoya Riyaz, Joshi Nandan, Singh Prerna, Erukulla Mounika
Internal Medicine, China Medical University, Shenyang, CHN.
Internal Medicine, Khaja Bandanawaz Institute of Medical Sciences, Gulbarga, IND.
Cureus. 2024 Apr 6;16(4):e57742. doi: 10.7759/cureus.57742. eCollection 2024 Apr.
Cardiovascular diseases (CVDs) continue to be a worldwide health concern, requiring effective strategies for risk reduction. This article explores the extensive collaboration between medical therapy and lifestyle modifications in the management of CVDs, aiming to interpret whether a single approach holds the key to reducing major cardiovascular events. In the realm of pharmaceutical therapy, statins, beta-blockers, angiotensin-converting-enzyme (ACE) inhibitors, and antiplatelet agents have shown significant effectiveness, as evidenced by landmark trials such as Scandinavian Simvastatin Survival Study (4S) and Heart Outcomes Prevention Evaluation (HOPE). Concurrently, lifestyle adjustments, encompassing physical activity, dietary changes, and management of stress, emerge as indispensable elements in cardiovascular care. The article discusses the pivotal role of patient adherence, tailored approaches, and the synergistic impact of combining medical therapy and lifestyle modifications. Challenges, such as socioeconomic disparities and uncertainties in lipid management, underscore the need for ongoing research and precision medicine. Digital health interventions offer novel avenues for personalized care. Despite advancements, uncertainties persist regarding the optimal balance between medical and lifestyle interventions in lowering major cardiovascular event risks. This article emphasizes the ongoing evolution of cardiovascular care, highlighting the imperative need for evidence-based guidelines tailored to individual patient needs.
心血管疾病(CVDs)仍然是一个全球范围内的健康问题,需要有效的风险降低策略。本文探讨了药物治疗与生活方式改变在心血管疾病管理中的广泛协作,旨在解读单一方法是否是降低主要心血管事件的关键。在药物治疗领域,他汀类药物、β受体阻滞剂、血管紧张素转换酶(ACE)抑制剂和抗血小板药物已显示出显著疗效,如北欧辛伐他汀生存研究(4S)和心脏结局预防评估(HOPE)等里程碑式试验所证明。与此同时,生活方式的调整,包括体育活动、饮食改变和压力管理,已成为心血管护理中不可或缺的要素。本文讨论了患者依从性、个性化方法以及药物治疗与生活方式改变相结合的协同作用的关键作用。社会经济差异和血脂管理的不确定性等挑战凸显了持续研究和精准医学的必要性。数字健康干预为个性化护理提供了新途径。尽管取得了进展,但在降低主要心血管事件风险方面,药物和生活方式干预的最佳平衡仍存在不确定性。本文强调心血管护理的不断发展,突出了根据个体患者需求制定循证指南的迫切需要。